新型替沃扎尼滴眼液治疗新生血管性年龄相关性黄斑变性的临床前眼部药代动力学与疗效
本研究在兔和猴中评估纳米晶化替沃扎尼(nTivo)滴眼液的眼部药代动力学和抗血管生成疗效。在色素兔中,nTivo滴眼液向视网膜/脉络膜的药物递送效率较微晶制剂最高提高9.5倍,提示纳米晶化增强后眼组织递送。在激光诱导脉络膜新生血管(CNV)模型猴中,nTivo滴眼液显著减小新生血管病变面积。
要点
- nTivo滴眼液在色素兔视网膜/脉络膜的递送效率较微晶制剂最高提高9.5倍。
- 重复滴眼后观察到眼部暴露蓄积,视网膜/脉络膜消除半衰期(247.5小时)长于血清(49.7小时)。
- 在猴CNV模型中,nTivo滴眼液显著减小新生血管病变面积。
核心结论
- nTivo滴眼液可能成为nAMD的潜在新治疗选择,基于纳米晶化和替沃扎尼黑色素结合特性带来的有利眼部药代动力学和抗血管生成特征。
研究设计与样本
- 在白化兔和色素兔中研究nTivo滴眼液与常规微晶化替沃扎尼滴眼液的眼部分布。
- 在激光诱导CNV模型猴中评估nTivo滴眼液的抗血管生成疗效。
主要发现
- 在色素兔中,nTivo滴眼液向视网膜/脉络膜的药物递送效率较微晶制剂最高提高9.5倍。
- 重复滴注nTivo滴眼液后观察到眼部暴露蓄积,视网膜/脉络膜中替沃扎尼的消除半衰期(247.5小时)长于血清(49.7小时)。
- 与白化兔相比,色素兔视网膜/脉络膜的暴露高3.2倍,消除半衰期长5.7倍。
- 在猴CNV模型中,nTivo滴眼液显著减小新生血管病变面积。
临床怎么用
- nTivo滴眼液作为非侵入性治疗nAMD的潜在选项,其纳米晶化和黑色素结合特性可能增强后眼递送和延长滞留。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In neovascular age-related macular degeneration (nAMD), invasive intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs is the current standard of care, highlighting the need for noninvasive eye drop formulations. We aimed to assess the ocular pharmacokinetics and anti-angiogenic efficacy of nanocrystallized tivozanib (nTivo) eye drops in rabbits and monkeys. METHODS: We investigated the ocular distribution of nTivo eye drops and conventional microcrystallized tivozanib eye drops in albino and pigmented rabbits. The anti-angiogenic efficacy of nTivo eye drops was evaluated in laser-induced choroidal neovascularization (CNV) model monkeys. RESULTS: In pigmented rabbits, nTivo eye drops showed up to 9.5-fold higher drug delivery efficiency to the retina/choroid relative to microcrystal formulations, indicating that nanocrystallization enhances the drug delivery efficiency of tivozanib to posterior eye tissues. Additionally, accumulation of the ocular exposure was observed with the repeated instillation of nTivo eye drops, and the elimination half-life (t1/2) of tivozanib was longer in the retina/choroid (247.5 hours) than in serum (49.7 hours). In comparison to albino rabbits, pigmented rabbits showed higher exposure (3.2-fold) and longer t1/2 (5.7-fold) in the retina/choroid, suggesting that the melanin binding properties of tivozanib potentially contribute to its accumulation and prolonged retention in the retina and choroid. In the monkey CNV model, nTivo eye drops significantly reduced the neovascularization lesion area. CONCLUSIONS: The nTivo eye drop formulation may be a potential new treatment option for nAMD due to its preferable ocular pharmacokinetic and anti-angiogenic profiles based on potential contributions of nanocrystallization and the melanin binding properties of tivozanib.
引用
- Satake K, Koshiba S, Haniuda H, et al. Preclinical Ocular Pharmacokinetics and Efficacy of Novel Tivozanib Eye Drops for Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2026. PMID: 42506959. doi:10.1167/iovs.67.8.55
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。